Cargando…

Serum butyrylcholinesterase predicts survival after extracorporeal membrane oxygenation after cardiovascular surgery

INTRODUCTION: Risk stratification in patients undergoing extracorporeal membrane oxygenation (ECMO) support after cardiovascular surgery remains challenging, because data on specific outcome predictors are limited. Serum butyrylcholinesterase demonstrated a strong inverse association with all-cause...

Descripción completa

Detalles Bibliográficos
Autores principales: Distelmaier, Klaus, Winter, Max-Paul, Rützler, Kurt, Heinz, Gottfried, Lang, Irene M, Maurer, Gerald, Koinig, Herbert, Steinlechner, Barbara, Niessner, Alexander, Goliasch, Georg
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4057519/
https://www.ncbi.nlm.nih.gov/pubmed/24479557
http://dx.doi.org/10.1186/cc13711
_version_ 1782320980485472256
author Distelmaier, Klaus
Winter, Max-Paul
Rützler, Kurt
Heinz, Gottfried
Lang, Irene M
Maurer, Gerald
Koinig, Herbert
Steinlechner, Barbara
Niessner, Alexander
Goliasch, Georg
author_facet Distelmaier, Klaus
Winter, Max-Paul
Rützler, Kurt
Heinz, Gottfried
Lang, Irene M
Maurer, Gerald
Koinig, Herbert
Steinlechner, Barbara
Niessner, Alexander
Goliasch, Georg
author_sort Distelmaier, Klaus
collection PubMed
description INTRODUCTION: Risk stratification in patients undergoing extracorporeal membrane oxygenation (ECMO) support after cardiovascular surgery remains challenging, because data on specific outcome predictors are limited. Serum butyrylcholinesterase demonstrated a strong inverse association with all-cause and cardiovascular mortality in non-critically ill patients. We therefore evaluated the predictive value of preoperative serum butyrylcholinesterase levels in patients undergoing venoarterial ECMO support after cardiovascular surgery. METHODS: We prospectively included 191 patients undergoing venoarterial ECMO therapy after cardiovascular surgery at a university-affiliated tertiary care center in our registry. RESULTS: All-cause and cardiovascular mortality were defined as primary study end points. During a median follow-up time of 51 months (IQR, 34 to 71) corresponding to 4,197 overall months of follow-up, 65% of patients died. Cox proportional hazard regression analysis revealed a significant and independent inverse association between higher butyrylcholinesterase levels and all-cause mortality with an adjusted hazard ratio (HR) of 0.44 (95% CI, 0.25 to 0.78; P = 0.005), as well as cardiovascular mortality, with an adjusted HR of 0.38 (95% CI, 0.21 to 0.70; P = 0.002), comparing the third with the first tertile. Survival rates were higher in patients within the third tertile of butyrylcholinesterase compared with patients within the first tertile at 30 days (68% versus 44%) as well as at 6 years (47% versus 21%). CONCLUSIONS: The current study revealed serum butyrylcholinesterase as a strong and independent inverse predictor of all-cause and cardiovascular mortality in patients undergoing venoarterial ECMO therapy after cardiovascular surgery. These findings advance the limited knowledge on risk stratification in patients undergoing ECMO support and represent a valuable addition for a comprehensive decision making before ECMO implantation.
format Online
Article
Text
id pubmed-4057519
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-40575192014-06-15 Serum butyrylcholinesterase predicts survival after extracorporeal membrane oxygenation after cardiovascular surgery Distelmaier, Klaus Winter, Max-Paul Rützler, Kurt Heinz, Gottfried Lang, Irene M Maurer, Gerald Koinig, Herbert Steinlechner, Barbara Niessner, Alexander Goliasch, Georg Crit Care Research INTRODUCTION: Risk stratification in patients undergoing extracorporeal membrane oxygenation (ECMO) support after cardiovascular surgery remains challenging, because data on specific outcome predictors are limited. Serum butyrylcholinesterase demonstrated a strong inverse association with all-cause and cardiovascular mortality in non-critically ill patients. We therefore evaluated the predictive value of preoperative serum butyrylcholinesterase levels in patients undergoing venoarterial ECMO support after cardiovascular surgery. METHODS: We prospectively included 191 patients undergoing venoarterial ECMO therapy after cardiovascular surgery at a university-affiliated tertiary care center in our registry. RESULTS: All-cause and cardiovascular mortality were defined as primary study end points. During a median follow-up time of 51 months (IQR, 34 to 71) corresponding to 4,197 overall months of follow-up, 65% of patients died. Cox proportional hazard regression analysis revealed a significant and independent inverse association between higher butyrylcholinesterase levels and all-cause mortality with an adjusted hazard ratio (HR) of 0.44 (95% CI, 0.25 to 0.78; P = 0.005), as well as cardiovascular mortality, with an adjusted HR of 0.38 (95% CI, 0.21 to 0.70; P = 0.002), comparing the third with the first tertile. Survival rates were higher in patients within the third tertile of butyrylcholinesterase compared with patients within the first tertile at 30 days (68% versus 44%) as well as at 6 years (47% versus 21%). CONCLUSIONS: The current study revealed serum butyrylcholinesterase as a strong and independent inverse predictor of all-cause and cardiovascular mortality in patients undergoing venoarterial ECMO therapy after cardiovascular surgery. These findings advance the limited knowledge on risk stratification in patients undergoing ECMO support and represent a valuable addition for a comprehensive decision making before ECMO implantation. BioMed Central 2014 2014-01-30 /pmc/articles/PMC4057519/ /pubmed/24479557 http://dx.doi.org/10.1186/cc13711 Text en Copyright © 2014 Distelmaier et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited.
spellingShingle Research
Distelmaier, Klaus
Winter, Max-Paul
Rützler, Kurt
Heinz, Gottfried
Lang, Irene M
Maurer, Gerald
Koinig, Herbert
Steinlechner, Barbara
Niessner, Alexander
Goliasch, Georg
Serum butyrylcholinesterase predicts survival after extracorporeal membrane oxygenation after cardiovascular surgery
title Serum butyrylcholinesterase predicts survival after extracorporeal membrane oxygenation after cardiovascular surgery
title_full Serum butyrylcholinesterase predicts survival after extracorporeal membrane oxygenation after cardiovascular surgery
title_fullStr Serum butyrylcholinesterase predicts survival after extracorporeal membrane oxygenation after cardiovascular surgery
title_full_unstemmed Serum butyrylcholinesterase predicts survival after extracorporeal membrane oxygenation after cardiovascular surgery
title_short Serum butyrylcholinesterase predicts survival after extracorporeal membrane oxygenation after cardiovascular surgery
title_sort serum butyrylcholinesterase predicts survival after extracorporeal membrane oxygenation after cardiovascular surgery
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4057519/
https://www.ncbi.nlm.nih.gov/pubmed/24479557
http://dx.doi.org/10.1186/cc13711
work_keys_str_mv AT distelmaierklaus serumbutyrylcholinesterasepredictssurvivalafterextracorporealmembraneoxygenationaftercardiovascularsurgery
AT wintermaxpaul serumbutyrylcholinesterasepredictssurvivalafterextracorporealmembraneoxygenationaftercardiovascularsurgery
AT rutzlerkurt serumbutyrylcholinesterasepredictssurvivalafterextracorporealmembraneoxygenationaftercardiovascularsurgery
AT heinzgottfried serumbutyrylcholinesterasepredictssurvivalafterextracorporealmembraneoxygenationaftercardiovascularsurgery
AT langirenem serumbutyrylcholinesterasepredictssurvivalafterextracorporealmembraneoxygenationaftercardiovascularsurgery
AT maurergerald serumbutyrylcholinesterasepredictssurvivalafterextracorporealmembraneoxygenationaftercardiovascularsurgery
AT koinigherbert serumbutyrylcholinesterasepredictssurvivalafterextracorporealmembraneoxygenationaftercardiovascularsurgery
AT steinlechnerbarbara serumbutyrylcholinesterasepredictssurvivalafterextracorporealmembraneoxygenationaftercardiovascularsurgery
AT niessneralexander serumbutyrylcholinesterasepredictssurvivalafterextracorporealmembraneoxygenationaftercardiovascularsurgery
AT goliaschgeorg serumbutyrylcholinesterasepredictssurvivalafterextracorporealmembraneoxygenationaftercardiovascularsurgery